RecruitingPhase 1NCT05304377
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
Studying Chronic myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Enliven Therapeutics
- Intervention
- ELVN-001(drug)
- Enrollment
- 250 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2027
Study locations (30)
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Montefiore Medical Center, The Bronx, New York, United States
- Oregon Health & Science University-Knight Cardiovascular Institute, Portland, Oregon, United States
- The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- Royal Adelaide Hospital, Adelaide, Australia
- UZ Gent, Ghent, Belgium
- UZ Leuven, Leuven, Belgium
- CHU Liege, Liège, Belgium
- University Health Network (UHN) - Princess Margaret Cancer Centre, Toronto, Ontario, Canada
- CHU Amiens Picardie Site Sud, Amiens, France
- Institut Bergonie - Centre Regional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest, Bordeaux, France
- CHRU de Lille - Hopital Calmette-Boulevard du Pr Leclercq CHRU Lille, Lille, France
- Centre Hospitalier Universitaire (CHU) De Limoges Hopital Dupuytren, Limoges, France
- Centre Leon Berard, Lyon, France
- Centre Hospitalier Lyon Sud, Pierre-Bénite, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05304377 on ClinicalTrials.govOther trials for Chronic myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07354074Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPNovartis Pharmaceuticals
- RECRUITINGNCT07375355Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in ChinaNovartis Pharmaceuticals
- ENROLLING BY INVITATIONNCT07383298Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated PhaseQian Jiang
- RECRUITINGPHASE2NCT06817720Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseM.D. Anderson Cancer Center
- RECRUITINGNCT07061145A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid LeukemiaAzienda USL Reggio Emilia - IRCCS
- RECRUITINGPHASE2NCT06409936PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLGruppo Italiano Malattie EMatologiche dell'Adulto
- RECRUITINGPHASE2NCT06514534Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.Novartis Pharmaceuticals
- RECRUITINGPHASE1NCT06787144ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese ParticipantsEnliven Therapeutics